VMP (Bortezomib, melphalan, and prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study

Journal of Clinical Oncology

Volumn 27, Issue 36, 2009, Pages 6086-6093

  Dimopoulos, Meletios A ^a   Richardson, Paul G ^a   Schlag, Rudolf ^a   Khuageva, Nuriet K ^a   Shpilberg, Ofer ^a   Kastritis, Efstathios ^a   Kropff, Martin ^a   Petrucci, Maria T ^a   Delforge, Michel ^a   Alexeeva, Julia ^a   Schots, Rik ^a   Masszi, Tamás ^a   Mateos, Maria Victoria ^a   Deraedt, William ^a   Liu, Kevin ^a   Cakana, Andrew ^a   Van De Velde, Helgi ^a   San Miguel, Jesús F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MELPHALAN; PREDNISONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEURALGIA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; KAPLAN MEIER METHOD; KIDNEY DISEASE; MULTIVARIATE ANALYSIS; PHASE 3 CLINICAL TRIAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY DISEASES; MALE; MELPHALAN; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; PYRAZINES; TREATMENT OUTCOME;

EID: 74949121208     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.22.2232     Document Type: Article

References (38)

1. Knudsen LM, Hippe E, Hjorth M, et al: Renal function in newly diagnosed multiple myeloma-a demographic study of 1353 patients: The Nordic Myeloma Study Group. Eur J Haematol 53:207-212,1994
2. Dimopoulos MA, Kastritis E, Rosinol L, et al: Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia 22:1485-1493, 2008
3. Knudsen LM, Hjorth M, Hippe E: Renal failure in multiple myeloma: Reversibility and impact on the prognosis-Nordic Myeloma Study Group. Eur J Haematol 65:175-181, 2000
4. Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma: Pathogenesis and prognostic implications. Arch Intern Med 150:1693-1695, 1990
5. Bladé J, Fernandez-Llama P, Bosch F, et al: Renal failure in multiple myeloma: Presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 158:1889-1893,1998
6. Eleutherakis-Papaiakovou V, Bamias A, Gika D, et al: Renal failure in multiple myeloma: Incidence, correlations, and prognostic significance. Leuk Lymphoma 48:337-341, 2007
7. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21-33, 2003
8. Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
9. Abbott KC, Agodoa LY: Multiple myeloma and light chain-associated nephropathy at end-stage renal disease in the United States: Patient characteristics and survival. Clin Nephrol 56:207-210, 2001
10. Carlson K, Hjorth M, Knudsen LM: Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure: A retrospective analysis and recommendations for dose adjustment. Br J Haematol 128:631-635, 2005
11. Chen N, Lau H, Kong L, et al: Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 47:1466-1475, 2007
12. Greipp PR, San Miguel J, Durie BG, et al: International staging system for multiple myeloma. J Clin Oncol 23:3412-3420, 2005
13. Kastritis E, Anagnostopoulos A, Roussou M, et al: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 92:546-549,2007
14. Sakhuja V, Jha V, Varma S, et al: Renal involvement in multiple myeloma: A 10-year study. Ren Fail 22:465-477, 2000
15. Dimopoulos MA, Roussou M, Gavriatopoulou M, et al: Reversibility of renal impairment in patients with multiple myeloma treated with bortezomibbased regimens: Identification of predictive factors. Clin Lymphoma Myeloma 9:302-306, 2009
16. Ailawadhi S, Mashtare TL, Coignet MV, et al: Renal dysfunction does not affect clinical response in multiple myeloma (MM) patients treated with bortezomib-based regimens. Blood 110:442a, 2007 (suppl; abstr 1477)
17. Bladé J, Sonneveld P, San Miguel JF, et al: Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 8:352-355, 2008
18. Chanan-Khan AA, Kaufman JL, Mehta J, et al: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 109:2604-2606,2007
19. Jagannath S, Barlogie B, Berenson JR, et al: Bortezomib in recurrent and/or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 103:1195-1200,2005
20. Ludwig H, Drach J, Graf H, et al: Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica 92:1411-1414, 2007
21. Ludwig H, Adam Z, Hajek R, et al: Bortezomibdoxorubicin-dexamethasone (BDD) for reversal of acute light chain induced renal failure (ARF) in multiple myeloma (MM): Results from a phase II study. Blood 112:1261a, 2008 (suppl; abstr 3682)
22. Roussou M, Kastritis E, Migkou M, et al: Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 49:890-895, 2008
23. San-Miguel JF, Richardson PG, Sonneveld P, et al: Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia 22:842-849, 2008
24. Millennium Pharmaceuticals Inc: VELCADE® (bortezomib) for Injection: Prescribing information. Cambridge, MA; Issued June 2008, Rev 9, 2008
25. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
26. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT. Br J Haematol 102:1115-1123, 1998
27. Bauer C, Melamed ML, Hostetter TH: Staging of chronic kidney disease: Time for a course correction. J Am Soc Nephrol 19:844-846, 2008
28. Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 139:137-147, 2003
29. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24:3113-3120, 2006
30. San Miguel JF, Schlag R, Khuageva NK, et al: Updated follow-up and results of subsequent therapy in the phase III VISTA trial: Bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood 112:242A, 2008 (suppl; abstr 650)
31. Durie BG, Kyle RA, Belch A, et al: Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J 4:379-398, 2003
32. Kyle RA, Rajkumar SV: Multiple myeloma. N Engl J Med 351:1860-1873, 2004
33. Gentile M, Ciolli S, Petrucci MT, et al: Bortezomib (VEL) based regimens in multiple myeloma (MM) patients with renal impairment (RI): A preliminary retrospective Italian multicenter study. Blood 112:1260a-1261a, 2008 (suppl; abstr 3681)
34. Gladney SP, Lonial S, Kaufman JL: Multiple myeloma presenting with advanced renal failure: A case report and new treatment options. Clin Lymphoma Myeloma 8:52-54, 2008
35. Malani AK, Gupta V, Rangineni R: Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol 116:255-258, 2006
36. Mohrbacher A, Levine AM: Reversal of advanced renal dysfunction on bortezomib treatment in multiple myeloma patients. J Clin Oncol 23:612s, 2005 (suppl; abstr)
37. Hojs R, Bevc S, Ekart R, et al: Serum cystatin C as an endogenous marker of renal function in patients with mild to moderate impairment of kidney function. Nephrol Dial Transplant 21:1855-1862,2006
38. Terpos E, Katodritou E, Tsiftsakis E, et al: Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration. Haematologica 94:372-379, 2009